Cholestasis

Progressive familial intrahepatic cholestasis type 3 (PFIC3) can cause abnormalities in copper metabolism that mimic another condition, Wilson’s disease, and early distinction is key…

Volixibat, Mirum Pharmaceuticals’ experimental oral treatment, may help reduce circulating bile acids and ease itch in pregnant women with intrahepatic cholestasis of pregnancy…

Health Canada has approved Mirum Pharmaceuticals’ oral therapy Livmarli (maralixibat) for cholestatic pruritus — that is, itching due to impaired bile flow —…

February is Rare Liver Diseases Month, and this year, the Global Liver Institute (GLI) is highlighting the importance of early diagnosis for better health…

An international group of patients, clinicians, and researchers has recommended a standardized set of clinical measurements to assess outcomes in intrahepatic cholestasis of pregnancy…

A global clinical trial testing Mirum Pharmaceuticals‘ maralixibat for treatment-resistant itching, or pruritus, associated with rare cholestatic conditions is expected to complete patient…

Low vitamin D levels in the first trimester of pregnancy are significantly associated with an increased risk of developing intrahepatic cholestasis of pregnancy (ICP),…

Two plant-based compounds — ferulic acid and wogonin — may help protect the liver in cholestasis by influencing the growth of certain gut bacteria,…

Women who develop severe intrahepatic cholestasis of pregnancy (ICP) at a later time in pregnancy have a higher risk of stillbirth, a study shows.

About half of children with progressive familial intrahepatic cholestasis (PFIC) were found to have cirrhotic cardiomyopathy (CCM), a form of heart disease, in a…